Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies to treat glaucoma and other serious diseases of the eye. The Company's most advanced product candidate, trabodenoson, is a highly selective adenosine mimetic and the first potential treatment for glaucoma of its kind. 

Trabodenoson has high lipid solubility which results in high ocular penetration, allowing it to reach target tissues with topical administration. In addition, it exhibits high tissue compatibility with the often sensitive tissues in the front of the eye which may reduce the risk of side effects.

TypePublic
HQLexington, US
Founded1996
Size (employees)24 (est)+27%
Websiteinotekpharma.com
Inotek Pharmaceuticals was founded in 1996 and is headquartered in Lexington, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Inotek Pharmaceuticals Office Locations

Inotek Pharmaceuticals has an office in Lexington
Lexington, US (HQ)
33 Hayden Avenue
Show all (1)
Report incorrect company information

Inotek Pharmaceuticals Financials and Metrics

Inotek Pharmaceuticals Revenue

USD

Net income (Q3, 2018)

(16.1m)

EBIT (Q3, 2018)

(15.3m)

Market capitalization (22-Dec-2017)

50.2m

Cash (30-Sep-2018)

38.1m
Inotek Pharmaceuticals's current market capitalization is $50.2 m.
Annual
USDFY, 2015FY, 2016FY, 2017

General and administrative expense

7.8m9.9m12.5m

R&D expense

12.6m32.0m14.2m

Operating expense total

20.4m41.9m26.7m

EBIT

(20.4m)(41.9m)(26.7m)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

General and administrative expense

2.0m1.7m1.8m2.5m2.3m2.3m2.9m2.2m3.9m8.7m4.1m2.3m

R&D expense

1.1m2.0m3.6m7.6m6.5m8.4m7.1m3.6m2.8m5.7m10.8m13.1m

Operating expense total

3.0m3.7m5.4m10.1m8.8m10.7m10.0m5.9m6.7m14.4m14.9m15.3m

EBIT

(3.0m)(3.7m)(5.4m)(10.1m)(8.8m)(10.7m)(10.0m)(5.9m)(6.7m)(14.4m)(14.9m)(15.3m)
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

80.0m29.8m78.7m

Inventories

1.1m1.9m

Current Assets

112.4m128.3m101.0m

PP&E

812.0k1.1m563.0k
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

53.1m49.0m89.2m58.7m38.5m83.0m25.3m27.6m49.1m171.1m52.5m38.1m

Current Assets

53.4m49.5m119.2m103.2m98.7m138.9m116.6m109.8m103.9m184.8m134.6m128.8m

PP&E

29.0k756.0k790.0k976.0k1.0m1.1m1.1m615.0k1.1m976.0k1.2m

Goodwill

30.8m30.8m30.8m
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

(68.0m)(42.9m)(29.5m)

Depreciation and Amortization

45.0k169.0k200.0k

Accounts Payable

487.0k(41.0k)(1.1m)

Cash From Operating Activities

(17.4m)(37.3m)(26.1m)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(1.5m)(3.8m)(56.0m)(10.1m)(18.8m)(29.9m)(10.7m)(17.2m)(24.6m)(15.3m)(31.1m)(47.2m)

Depreciation and Amortization

1.0k6.0k37.0k72.0k111.0k61.0k124.0k162.0k83.0k157.0k233.0k

Accounts Payable

154.0k(333.0k)563.0k(257.0k)(712.0k)144.0k310.0k(1.2m)(1.2m)(2.3m)1.3m2.7m

Cash From Operating Activities

(2.0m)(6.0m)(10.4m)(9.0m)(17.0m)(26.1m)(11.6m)(17.5m)(23.1m)(11.6m)(21.3m)(33.0m)
USDY, 2018

Financial Leverage

1.4 x
Show all financial metrics

Inotek Pharmaceuticals Operating Metrics

FY, 2016

Patent Portfolios

1

Phase III Trials Products

1
Show all operating metrics
Report incorrect company information

Inotek Pharmaceuticals Blogs

Rocket Pharmaceuticals Prices Public Offering of Common Stock

NEW YORK--(BUSINESS WIRE)--Nov. 27, 2018-- Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) (“Rocket”) today announced the pricing of an underwritten public offering of 3,550,000 shares of its common stock at a public offering price of $15.50 per share. The gross proceeds to Rocket…

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations for RP-L102 Gene Therapy for Fanconi Anemia

- Global Trial of RP-L102 Utilizing No Conditioning and “Process B” On Track for Early 2019 - NEW YORK--(BUSINESS WIRE)--Nov. 27, 2018-- Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces that …

Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock

NEW YORK--(BUSINESS WIRE)--Nov. 26, 2018-- Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) (“Rocket”) today announced that it has commenced an underwritten public offering of $50,000,000 of shares of its common stock. Rocket also intends to grant the underwriters a 30-day option t…

Rocket Pharmaceuticals and REGENXBIO Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector

- REGENXBIO grants Rocket exclusive, worldwide rights to NAV AAV9 for the development and commercialization of treatments for Danon Disease - - Investigational New Drug Application Expected to be Filed in 2019; Clinical Trial to Follow - NEW YORK & ROCKVILLE, Md.--(BUSINESS…

Rocket Pharmaceuticals Announces Preclinical Data for AAV-Based RP-A501, the First Investigational Gene Therapy Program for a Monogenic Heart Failure Syndrome

- Preclinical Data Package Shows Dose-Dependent Survival, Functional, Structural, and Molecular Benefits with No Safety or Tolerability Issues Observed - - RP-A501’s Market Opportunity: 15,000-30,000 Estimated Prevalence in the U.S. and E.U. - - RP-A501 Anticipated to E…

Rocket Pharmaceuticals to Host Conference Call to Reveal First AAV Gene Therapy Program

Conference Call Scheduled for Monday, November 26, 2018, at 8:30 a.m. ET NEW YORK--(BUSINESS WIRE)--Nov. 25, 2018-- Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces that management wil…
Show more

Inotek Pharmaceuticals Company Life and Culture

Report incorrect company information

Inotek Pharmaceuticals Frequently Asked Questions

  • When was Inotek Pharmaceuticals founded?

    Inotek Pharmaceuticals was founded in 1996.

  • How many employees does Inotek Pharmaceuticals have?

    Inotek Pharmaceuticals has 24 employees.

  • Who are Inotek Pharmaceuticals competitors?

    Competitors of Inotek Pharmaceuticals include MyoKardia, Athersys and Ironwood Pharmaceuticals.

  • Where is Inotek Pharmaceuticals headquarters?

    Inotek Pharmaceuticals headquarters is located at 33 Hayden Avenue, Lexington.

  • Where are Inotek Pharmaceuticals offices?

    Inotek Pharmaceuticals has an office in Lexington.

  • How many offices does Inotek Pharmaceuticals have?

    Inotek Pharmaceuticals has 1 office.